Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
MeSH Number(s)
D08.811.913.696.620.682.725.400.950
D12.776.543.750.060.750
D12.776.543.750.750.400.910
Concept/Terms
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Permeability Factor
- Vascular Endothelial Cell Growth Factor Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- VEGF Receptors
- Receptors, VEGF
- VPF Receptor
- Receptor, Vascular Endothelial Cell Growth Factor
- Vascular Permeability Factor Receptor
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 3 | 3 |
1995 | 0 | 8 | 8 |
1996 | 0 | 9 | 9 |
1997 | 0 | 8 | 8 |
1998 | 0 | 9 | 9 |
1999 | 0 | 7 | 7 |
2000 | 0 | 15 | 15 |
2001 | 0 | 21 | 21 |
2002 | 0 | 17 | 17 |
2003 | 1 | 3 | 4 |
2004 | 1 | 3 | 4 |
2005 | 5 | 4 | 9 |
2006 | 3 | 3 | 6 |
2007 | 5 | 8 | 13 |
2008 | 4 | 6 | 10 |
2009 | 4 | 15 | 19 |
2010 | 6 | 8 | 14 |
2011 | 3 | 9 | 12 |
2012 | 9 | 11 | 20 |
2013 | 9 | 9 | 18 |
2014 | 16 | 8 | 24 |
2015 | 15 | 7 | 22 |
2016 | 10 | 11 | 21 |
2017 | 8 | 7 | 15 |
2018 | 6 | 7 | 13 |
2019 | 8 | 7 | 15 |
2020 | 6 | 6 | 12 |
2021 | 1 | 14 | 15 |
2022 | 1 | 10 | 11 |
2023 | 0 | 4 | 4 |
2024 | 1 | 1 | 2 |
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 04; 29(3):254-262.
-
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Cancer Immunol Immunother. 2024 Jan 18; 73(1):17.
-
Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen. Eye (Lond). 2024 01; 38(1):161-167.
-
Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. JAMA Ophthalmol. 2023 03 01; 141(3):268-274.
-
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023 02 07; 329(5):376-385.
-
IL-36? Augments Ocular Angiogenesis by Promoting the Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Axis. Am J Pathol. 2023 11; 193(11):1740-1749.
-
The Effect of Sample Medication Use on Subsequent Anti-VEGF Agent Selection for Neovascular Age-Related Macular Degeneration. Semin Ophthalmol. 2022 Oct-Nov; 37(7-8):902-908.
-
Tivozanib for the treatment of advanced renal cell carcinoma. Expert Opin Pharmacother. 2022 Jul; 23(10):1135-1142.
-
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 08 25; 387(8):692-703.
-
TWO-YEAR RESULTS OF INTRAVITREAL INJECTIONS OF AFLIBERCEPT IN COATS DISEASE: A CASE REPORT. Retin Cases Brief Rep. 2022 Jul 01; 16(4):473-478.